Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. (Rigel), incorporated in June 1996, is a clinical-stage drug development company. The Company discovers and develops small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases. Its research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The Company has product development programs in inflammatory/autoimmune diseases, such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

Company Growth (employees)
Type
Public
HQ
South San Francisco, US
Founded
1996
Size (employees)
77 (est)-38%
Website
rigel.com
Rigel Pharmaceuticals was founded in 1996 and is headquartered in South San Francisco, US

Key People at Rigel Pharmaceuticals

James M. Gower

James M. Gower

CEO
Frank Torti

Frank Torti

Investor
Raul R. Rodriguez

Raul R. Rodriguez

President, COO
Elliott B. Grossbard

Elliott B. Grossbard

EVP, Development CMO

Rigel Pharmaceuticals Office Locations

Rigel Pharmaceuticals has an office in South San Francisco
South San Francisco, US (HQ)
1180 Veterans Boulevard

Rigel Pharmaceuticals Data and Metrics

Rigel Pharmaceuticals Financial Metrics

Numbers are in $, USD

Market capitalization (25-May-2017)

296.3 m

Closing share price (25-May-2017)

2.5

Cash (31-Dec-2016)

17.6 m
Rigel Pharmaceuticals's current market capitalization is $296.3 m.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

20.9 m15.2 m43.5 m17.6 m

Accounts Receivable

5.8 m5.8 m203 k

Inventories

Current Assets

220.1 m150.5 m129 m76.2 m

PP&E

4.5 m2.5 m1.6 m1.2 m

Total Assets

226.1 m154.1 m131.7 m78.1 m

Accounts Payable

3.9 m1.6 m2.8 m5.6 m

Current Liabilities

10.3 m14 m33.8 m22.6 m

Additional Paid-in Capital

1.1 b1.1 b1.1 b1.1 b

Retained Earnings

(849.3 m)(940.2 m)(991.6 m)(1.1 b)

Total Equity

208.3 m128.2 m91.4 m55 m

Financial Leverage

1.1 x1.2 x1.4 x1.4 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(89 m)(90.9 m)(51.5 m)(69.2 m)

Depreciation and Amortization

2.6 m2.4 m1.4 m941 k

Accounts Receivable

(5.8 m)(5.8 m)5.5 m203 k

Inventories

1.9 m722 k

Accounts Payable

2.2 m(2.3 m)1.2 m2.8 m

Cash From Operating Activities

(86.1 m)(69.8 m)(23.4 m)(75.9 m)

Capital Expenditures

(1.2 m)(413 k)(546 k)(804 k)

Cash From Investing Activities

72.4 m62.9 m44.6 m24.9 m

Cash From Financing Activities

1.1 m1.2 m7.1 m25.2 m

Free Cash Flow

(84.8 m)(69.3 m)(22.9 m)(75.1 m)
Y, 2016

Financial Leverage

1.4 x

Rigel Pharmaceuticals Market Value History

Rigel Pharmaceuticals Online and Social Media Presence

Rigel Pharmaceuticals Company Life and Culture

You may also be interested in